Kentucky Cannabis Company • 2026 State of the Industry Report

A perspective from Kentucky Cannabis Company on why hemp policy should move closer to genetics, chemotype verification, whole-plant profiling, and transparent manufacturing standards.

By Bill Polyniak, Founder, Kentucky Cannabis Company

• For nearly 50 years, hemp policy has leaned on a number that began as a taxonomic guide, not a complete biological definition of the plant.
• Both what the law calls “hemp” and what it calls “marijuana” are still Cannabis sativa L.
• What matters biologically is the plant’s underlying chemotype and genetic tendency toward CBDA-dominant or THCA-dominant expression.
• Kentucky can lead by moving closer to genetic verification, whole-plant profiling, and transparent manufacturing standards.

I have spent more than a decade watching the hemp industry build itself around a number that was never designed to carry this much weight.

The 0.3% THC limit has become the line between “legal” and “illegal” hemp in the public mind. But that line did not come down from nature. It came from a scientific classification framework published in 1976, where Small and Cronquist explicitly described 0.30% delta-9-THC as an arbitrarily adopted guide for distinguishing classes of cannabis plants. Over time, that guide hardened into policy, and policy hardened into dogma.

That distinction matters. A taxonomic distinction can be useful. A compliance threshold can be practical. But neither one should be confused with the full biological identity of a living plant.

From where I sit, the cost of that confusion has been enormous. Since the early pilot-program era in Kentucky, growers and breeders have been pushed to chase compliance first. Instead of asking, “What is this plant genetically built to express?” the industry has too often asked, “How close can we get to the line without crossing it?” That is not a breeding philosophy. That is defensive farming.

Here is the truth that the industry needs to say more plainly: the difference between “hemp” and “marijuana” is not that one is a different species. They are both Cannabis sativa L. The more meaningful biological difference is the plant’s genetic and biochemical tendency to produce certain cannabinoids over others.

Researchers commonly describe three primary chemical phenotypes in cannabis. Type I plants are THC-dominant. Type II plants are more balanced. Type III plants are CBD-dominant. A true Type III plant is biologically oriented toward CBDA as its primary expression, with THC present as a minor part of the profile rather than the defining feature.

This is where the law loses the plot. A Type III plant does not stop being biologically Type III because an environmental condition, harvest window, or maturation curve nudges one test result above a legal line. And a plant does not become more authentic hemp simply because it was bred to stay safely small in all the wrong ways.

You do not change plant identity with a compliance spreadsheet.

That is why hemp should be judged first by its genetic heritage and chemotype stability, then by transparent testing and responsible manufacturing. The decimal matters legally. It does not tell the whole biological truth.

This comparison shows the gap between the current legal shorthand and the fuller biological picture of what a true Type III hemp plant represents. The left side reflects the compliance framework most people recognize today, while the right side shows the plant-based reality that genetics, chemotype, and full-spectrum expression reveal.

The biggest casualty of the 0.3% framework is not just farmer frustration. It is the discovery gap the framework has created across the rest of the plant.

Kentucky’s cannabinoid-product framework already reflects a broader chemical reality. The state recognizes a range of non-intoxicating cannabinoids in its regulatory materials, including CBD, CBDA, CBDV, CBC, CBGA, CBG, CBN, and CBT. That matters because it shows that the plant’s value has never been limited to one or two headline compounds.

At the same time, cannabis is a chemically complex plant with multiple recognized chemotypes and a much wider metabolite profile than a basic THC/CBD summary can capture.

When breeders are forced to optimize primarily for compliance, they are not just limiting THC. They are narrowing the window for broader expression across the plant. Harvest timing alone can materially change cannabinoid accumulation. In practical terms, pressure to harvest or breed around one legal number can reshape the finished profile that reaches the bottle.

That is the real loss. We have spent years building a “CBD-first” industry while too often underinvesting in the deeper chemistry of Type III hemp. We have not given enough attention to what full-profile Kentucky hemp can teach us about minor cannabinoids, aromatic compounds, and formulation quality when the plant is allowed to express itself more honestly.

At Kentucky Cannabis Company, our bloom-focused philosophy matters because it respects the most information-rich part of the plant and aims to preserve as much of that character as possible through careful processing and documentation.

Kentucky has an opportunity to lead the next phase of this industry, but only if we are willing to think beyond prohibition-lite logic.

For too long, the success or failure of a hemp crop has been reduced to a single post-harvest snapshot. That approach may be administratively simple, but it is biologically incomplete. It ignores the fact that cannabinoid expression is tied to genetics, plant development, and environmental conditions.

A better standard would include three things.

First, genetic benchmarking. If a cultivar is consistently verified as Type III, that should matter. It should not replace safety testing, but it should inform how the plant is understood and regulated.

Second, whole-plant valuation. Success should be measured by the total cannabinoid and terpene profile, not by one number treated as if it were the plant’s sole identity.

Third, real full-spectrum transparency. If a product is labeled full spectrum, that claim should be supported by meaningful batch documentation, not marketing language.

Kentucky is already moving toward more structured oversight of hemp-derived cannabinoid products through registration, processing, manufacturing, sampling, testing, labeling, and packaging rules. The next step should be smarter biology, not just tighter paperwork.

As I look at the next decade, my position is straightforward: let the biology of the plant speak first. Let DNA, chemotype, and bloom integrity tell us what hemp is. Then let responsible manufacturing and transparent testing show the public exactly what is in the final product.

That is the kind of standard Kentucky should be known for.

Explore our lab-tested products, review batch documentation, and learn more about how Kentucky Cannabis Company approaches full-spectrum hemp with transparency and care.